Most Read Articles
Roshini Claire Anthony, 3 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

VYC-17.5L effective, safe for nasolabial folds

07 Jul 2017

VYC-17.5L (17.5 mg/mL hyaluronic acid, 0.3 percent lidocaine) has a good 1-year safety and effectivity profile for the treatment of moderate and severe nasolabial folds (NLF), a new study reveals.

The 70 participants (mean age 49±10 years; 94 percent female) with NLFs showed significant improvement in the primary endpoint of NLF severity in the left (mean change, -0.8± 0.8) and right (mean change, -0.8±0.7) NLFs at 12 months compared with baseline (p<0.0001).

Improvements in left and right NLF severity were also significant after the final treatment (mean changes, -2.0 and -1.9, respectively), after 1 month (mean change, -1.7 and -1.8, respectively) and after 9 months (mean change, -1.3 and -1.2, respectively; p<0.001 for all).

Mean investigator satisfaction scores ranged from 4.0±1.0 to 4.6±0.6 out of a maximum of 5 scores, while patient confidence scores were significantly higher after treatment compared with baseline.

Majority (n=67; 82.1 percent) of the patients were able to return to normal daily activity within 24 hours; four reported requiring recovery of 4 to 8 days before returning to normal activity.

Out of a maximum pain rating of 10, mean ratings were 2.0±1.8 for either side immediately after treatment. Pain ratings decreased to 0.7±1.5 and 0.8±1.7 for the left and right sides, respectively, after 14 days.

Initial swelling scores were 1.7±1.6 for either side and decreased to 1.4±2.2 and 1.5±2.2 for the left and right sides, respectively, at day 14. Bruising scores were initially 0.3±0.9 for both sides; ratings increased to 0.5±1.3 and 0.9±1.9 for left and right sides, respectively, after 14 days.

Only two adverse events were reported: reduced sensitivity, swelling and redness around the mouth (n=1), and swelling in the injection area (n=1). Both symptoms were resolved. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.